Skip to content

Lung Health and the Microbiome Among Adults in Botswana: the Go-hema Cohort

Determinants of Lung Health Among Batswana Adults With and Without HIV: the Go-Hema Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07699614
Enrollment
900
Registered
2026-07-13
Start date
2024-12-01
Completion date
2030-12-20
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Pulmonary Disease, Restrictive Pulmonary Disease

Brief summary

Chronic respiratory diseases like chronic obstructive pulmonary disease (COPD) are responsible for millions of deaths each year, the majority of which occur in low- and middle-income countries (LMICs). LMICs also have high rates of abnormal lung function, including restrictive spirometric pattern (RSP), which can precede the development of chronic respiratory diseases and is associated with all-cause mortality. Additionally, LMICs in sub-Saharan Africa are home to the majority of the world's population of people with HIV (PWH). HIV increases the risk of COPD and COPD associated mortality, but the mechanisms underlying this risk are incompletely understood.

Detailed description

To address the knowledge gap, the investigator propose a prospective cohort study to phenotype patterns of abnormal lung function and use multi-omics to identify associations between host-microbiome interactions, COPD, and lung function loss among adults with and without HIV in Botswana. The findings of this study will improve understanding of respiratory health and determinants of COPD among Batswana adults and contribute to the equitable development of novel COPD therapies by generating data from a population overrepresented in global COPD mortality but underrepresented in current COPD and microbiome research. Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. COPD affects nearly 300 million people globally and is the third leading cause of death.Despite advances in tobacco control programs, the prevalence of COPD is projected to increase as the global population ages, pneumonia incidence increases, and exposure to high levels of particulate air pollution persists. Additionally, COPD is a heterogenous disease with multiple partially understood phenotypes that exhibit varying responses to current therapies.Consequently, efforts to reduce incident COPD and COPD-associated mortality are complicated by challenges in reducing exposure to risk factors and an incomplete understanding of disease pathophysiology.

Interventions

None listed

Sponsors

Duke University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
35 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adults 35 years of age or older * In case at a clinic in Botswana * Documented HIV status * Ability to provide informed consent

Exclusion criteria

* Respiratory infection in the prior 4 weeks * Active pulmonary tuberculosis * Inability to perform spirometry including eye, abdominal, or * Thoracic surgery or myocardial infarction in the prior 6 weeks * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Duke Activity Status Index (DASI) score60 monthsThe DASI will be assessed over time to determine pulmonary function.
Six minute walk test60 monthsA six minute walk test will be assessed over time to determine pulmonary function.

Countries

Botswana

Contacts

CONTACTRelebogile Thipe, Nursing
thre2001@gmail.com+2673170933
CONTACTSweta Patel, Medical
sweta.patel@duke.edu: (919) 668-0325
PRINCIPAL_INVESTIGATORRobert Gross, Medical

University of Pennsylvania

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 14, 2026